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ISSObjective: To explore the levels and determinants of loss to follow-up (LTF) under
universal lifelong antiretroviral therapy (ART) for pregnant and breastfeeding women
(‘Option Bþ’) in Malawi.
Design, setting, and participants: We examined retention in care, from the date of ART
initiation up to 6 months, for women in the Option Bþ program. We analysed nationwide
facility-level data on women who started ART at 540 facilities (n¼21 939), as well as
individual-level data on patients who started ART at 19 large facilities (n¼11 534).
Results: Of the women who started ART under Option Bþ (n¼21 939), 17% appeared to
be lost to follow-up6 monthsafterART initiation.Most losses occurred in the first 3 months
of therapy.OptionBþpatientswhostarted therapyduringpregnancywerefive timesmore
likely thanwomenwhostartedART inWHO stage3/4orwith a CD4þcell count 350 cells/
ml or less, to never return after their initial clinic visit [odds ratio (OR) 5.0, 95% confidence
interval (CI) 4.2–6.1]. Option Bþ patients who started therapy while breastfeeding were
twiceas likely tomiss theirfirst follow-upvisit (OR2.2,95%CI1.8–2.8).LTFwashighest in
pregnant Option Bþ patients who began ART at large clinics on the day they were
diagnosed with HIV. LTF varied considerably between facilities, ranging from 0 to 58%.
Conclusion: Decreasing LTF will improve the effectiveness of the Option Bþ approach.
Tailored interventions, like community or family-based models of care could improve
its effectiveness.  2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:589–598Keywords: antiretroviral therapy, loss to follow-up, option Bþ, pregnancy,
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590 AIDS 2014, Vol 28 No 4Introduction predictors of loss to follow-up (LTF) across differentProgrammes that effectively prevent mother-to-child
transmission (PMTCT) of HIV can reduce the rate
of transmission under 5%, and reduce morbidity and
mortality in both mothers and children [1]. In 2010, the
WHO recommended lifelong antiretroviral therapy
(ART) for women who were eligible for treatment and
who had CD4þ cell counts 350 cells/ml or less, or in
WHO clinical stage 3 or 4. For women not yet eligible
for treatment, WHO recommended two alternative
PMTCT strategies for short-term antiretroviral prophy-
laxis. Option A started women on antepartum zidovudine
(AZT) from 14 weeks after pregnancy, as well as on
lamivudine (3TC) and nevirapine (NVP) during labour,
followed by a zidovudine (ZDV)/3TC tail for 7 days,
with daily infant NVP during breastfeeding. Option B
started women on triple-drug prophylaxis 14 weeks after
gestation, and continued throughout pregnancy and
breastfeeding [2,3]. These strategies depend on CD4þ cell
testing to determine women’s eligibility for lifelong ART
[4]. In a systematic review on sub-Saharan African
PMTCT programmes, CD4þ cell count testing was
identified as a major barrier to PMTCT [5].
In 2011, the Malawian Ministry of Health (MOH)
adopted a pragmatic public health approach to improve
the low PMTCT coverage in Malawi and implemented a
modified Option B, commonly referred to as Option Bþ
[6]. Option Bþ provides universal lifelong ART for all
HIV-infected pregnant and breastfeeding women,
regardless of CD4þ cell count and/or WHO clinical
stage. The policy was designed for the Malawian
healthcare system with its limited laboratory capacity,
and population with high HIV prevalence, short birth
intervals, and extended breastfeeding. It avoids CD4þ cell
count testing and continues ART even after women
discontinue breastfeeding [7,4].
Malawi’s initiative has sparked interest and debate among
the international public health community [4,8–11], and
the latest 2013 WHO guidelines recommend lifelong
ART for all pregnant and breastfeeding women [12].
Option Bþ may improve PMTCT and may also reduce
maternal morbidity and mortality [13], as well as
transmission between serodiscordant partners [14]. But
concerns about implementation, patient acceptability and
retention in care must be addressed [8].
Results of routine monitoring and evaluation (M&E) of
the Malawi HIV programme suggest that Option Bþ is
feasible and acceptable. The new PMTCT guidelines
increased antiretroviral coverage among pregnant women
from 49% in 2011 to 60% in 2012 [15]. Programmatic
data indicate that most women who started ARTwith an
Option Bþ indication were still in care after 6 months
(82.6%), and most of them were still in care after
12 months (76.9%) [6,16]. The exact timing andpyright © Lippincott Williams & Wilkins. Unauthosettings are unknown.
We describe retention in care for women who started
ARTunder Option Bþ using routine facility-level M&E
data and patient-level data from a subset of facilities with
an electronic medical record system (EMRS).Methods
Two complementary data sources were used to explore
facility and patient-level factors associated with LTF. We
first provide a summary of the Malawi ART/PMTCT
programme, and then describe the data sources, eligibility
criteria, definitions and statistical analysis separately for
facility and patient-level analyses.
Malawi National antiretroviral therapy/
prevention of mother-to-child transmission
programme
The scale-up of free ART started in 2004 using a simplified
protocol and standard ART regimens. It relied mainly on
clinical monitoring for toxicity and treatment failure. ART
patients are followed monthly for the first 6 months and
every 2–3 months thereafter. PMTCT was implemented
in 2002: single-dose NVP was given to the mother at the
onset of labour and to the infant after birth. In 2007, the
WHO ‘AZT combination prophylaxis’regimen was rolled
out, initially at district hospitals and larger facilities. Similar
to ‘Option A’, this regimen provides daily ZDV for the
mother during pregnancy with an additional dose of 3TC
and NVP during labour, and a 1–4-week prophylaxis with
ZDV-syrup for the infant [2,17]. When Option Bþ was
introduced in September 2011, pregnant and breastfeeding
women began to receive a simple fixed-dose combination
of tenofovir, 3TC and efavirenz [7]. Patients lost to follow-
up are not actively traced.
Facility-level data: eligibility, definitions and
statistical analysis
Each quarter, representatives from the MOH visit all
ART/PMTCT facilities in the country. They review the
treatment cards of all patients who started ART between
two and three quarters preceding the review, and extract
treatment outcomes at 6 and 12 months on therapy. ART
outcomes for women who started with an Option Bþ
indication are aggregated by facility. Routine M&E
methods are described in detail in the MOH quarterly
HIV Programme Reports [6,18]. We included all Option
Bþ patients who started ART between October 2011
and March 2012 at 540 facilities (Fig. 1). Patients who
transferred between facilities were excluded to prevent
double-counting.
Our primary outcome was the proportion of patients
‘lost to follow-up’ 6 months after they began ART. Inrized reproduction of this article is prohibited.
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Data on 23 297 option B+ patients starting
ART in 540 ART sites in quarter four 2011
and quarter one 2012 (510 sties with paper-
based records; 30 EMRS sites)
Facility-level data Individual-level data
158 855 patients from 20 sites with EMRS
One site because of poor data quality (n = 21 074)
Male patients (n = 53 057)
Non-naive patients or patients not on ART
(n = 1955)
Patients aged <16 years (n = 6833); >50 years
(n = 5158)
Patients started ART before the implementation of
option B+ (01/09/2011) (n = 59 151)
Patients with unknown reason for starting ART:
(n = 68)
Patients with unknown ART outcome: (n = 25)
11 534 eligible patients from 19 sites with EMRS (table 1)
Figure 3: Time from HIV testing to ART
initiation
Figure 2: ART outcomes since introduction of
option B+: n = 11 534
ART inititation <3 month before closure of
database (n = 2810)
Table 2: Predictors of no follow-up (n = 8724)
LTF at first visit (n = 905) or ART initiation <4
month before closure of DB (n = 1089)
Table 2: Predictors of LTF at second visit
(n = 6730)
Table 2: Predictors of LTF during months 3–6
on ART (n = 7196)
LTF at first or second visit (n = 1209)
Obs. end before enter (60 days) n = 3129
Excluded patients:
1358 patients transferred-out
excluded
21 939 patients
ART outcomes of option B+
patients 6 month after ART
initiation
Sites with ≤10 patients
registered excluded (848
patients from 172 sites)
Proportion of patients LTF per site
(21 091 patients from 368 sites)
Meta-analysis for site-level predictors
of LTF (21 091 patients from 368 sites)
Facility-level estimates for the
proportion of pregnant option B+
women failing to return to clinic after
ART start retrived from individual-level
data (19 EMRS-sites)
Figure S1, Table S1 : Meta-analysis for
site-level predictors of LTF among
option B+ pregnant women
EMRS: Electronic medical record system
ART: Antiretroviral therapy
LTF: Loss to follow-up
Fig. 1. Inclusion of facilities and patients in different analyses.facility-level data, we defined patients who missed an
appointment and did not return to care for more than
60 days as lost to follow-up. We calculated the proportion
of patients lost to follow-up in large facilities, which have
EMRS, and in smaller ART facilities, which have no
EMRS. For facilities where more than 10 patients were
registered (Fig. 1), we calculated the site-specific log odds
to get LTF and used random-effects meta-regression to
explore between-site variability. Results were trans-
formed to odds.
Patient-level data: eligibility, definitions and
statistical analysis
At larger facilities, individual-level data are collected with
an EMRS during patient consultation. The EMRS
system was introduced in 2006. It guides healthcareCopyright © Lippincott Williams & Wilkins. Unautworkers through treatment protocols and stores key data
for patient care [19]. Quality checks are implemented in
the system and manual checks are performed monthly. We
extracted patient-level data from all 20 facilities in Central
and Southern Malawi in which EMRS was in place when
the Option Bþ programme began. Data from five facilities
in Northern Malawi were not extracted because they used
a different database system with known data quality
problems. Of the 20 eligible facilities, one was excluded
becauseof serious data quality problems. Nineteen facilities
provided reliable data and were included.
We included all treatment-naive women aged 16–50 years
who started ART in the 19 facilities (Fig. 1) between
September 2011 (the date Option Bþ was implemented)
and the date of the most recent follow-up visit in a givenhorized reproduction of this article is prohibited.
Co
592 AIDS 2014, Vol 28 No 4facility (the closing date). We excluded women whose
reason for starting ART was unknown.
Our primary outcomes were ‘no follow-up visit after
ART initiation’ and LTF. We defined patients who missed
their first follow-up visit and did not return to care for
more than 60 days as ‘no-follow up after ART initiation’
on the day of the missed appointment. Patients who
missed a subsequent follow-up visit and did not return
to care for more than 60 days were classified as lost to
follow-up. We distinguished between no follow-up and
LTF by assuming that a woman’s failure to return for the
first follow-up visit might reflect her resistance to starting
ART, whereas we regarded her failure to return thereafter
as a problem of retention. Secondary outcomes included
the time from HIV diagnosis to ART initiation, death,
transfer out and stopped ART. We compared patient
outcomes across three groups, based on the indication for
ART: ‘ART for own health’ (non-pregnant female
patients in WHO clinical stage 3 or 4 or with CD4þ cell
count 350/ml); ‘Bþ pregnant’ (pregnant women
starting ART regardless of CD4þ cell count or clinical
stage); or ‘Bþ breastfeeding’ (breastfeeding women who
start ARTregardless of CD4þ cell count or clinical stage).
We plotted cause-specific cumulative incidence functions
for all ART outcomes by patient group. To examine
factors associated with no follow-up and LTF, we used
univariable and multivariable logistic regressions with a
random effect for the cohorts. We used competing risk
regression to examine variables associated with LTF after
the second follow-up visit. This model accounts for the
interdependence of LTF and competing events [20,21].
Models were adjusted for age (<30, 30–39, 40 years)
and facility type (health centre, mission, district or central
hospital). Patients were followed from initiation of ART
to the date of the outcome of interest, or were censored at
database closure or because they had completed 6 months
of follow-up. We collected additional information on
service delivery and ART preparation for the 19 EMRS
facilities to explore the association between these factors
and no follow-up visit among pregnant Option Bþ
women. For each facility, we assessed the percentage of
Bþ pregnant women who never came back after starting
ART and estimated the underlying mean percentage by
combining estimates for facilities in random-effect meta-
analysis. Results are shown in a forest plot. Meta
regression was used to study facility-level factors
associated with no follow-up visit among pregnant
Option Bþ patients. To show differences in the delay of
ART initiation among patients groups, we plotted
Kaplan–Meier curves. All analyses were done in Stata
version 11 (Stata Corp., College Station, Texas, USA).
Ethical approval
Ethical approval was granted by the Malawian Institu-
tional Review Board, the National Health Sciences
Research Committee (No: 962).pyright © Lippincott Williams & Wilkins. UnauthoRole of the funding source
The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.Results
Facility-level data
Included in the analysis were a total of 21 939 patients
who started ART under Option Bþ at one of 540
facilities from October 2011 to March 2012 and who did
not transfer to another facility (n¼ 1358 patients who
transferred out were excluded). At 6 months after ART
initiation, 17 984 (82.0%) were retained in care; 3749
(17.1%) were lost to follow-up; 151 (0.7%) were known
to have died and 53 (0.2%) were known to have stopped
ART. In EMRS sites, LTF was 22% and thus higher than
in other, usually smaller, facilities with paper-based
records in which 15.6% of all patients were lost to follow-
up. LTF varied considerably between 0 and 58% at the
368 facilities with more than 10 Option Bþ patients
registered. Overall, 137 (37.2%) facilities performed well
(<10% of all patients lost to follow-up 6 months after
ART initiation). LTF was moderate (10–19%) at 108
(29.4%) facilities and high (>20%) at 123 (33.4%) facili-
ties.
There was no clear association between facility-level
predictors and LTF. There was, however, a tendency
towards higher LTF in urban facilities than in rural
facilities [odds ratio (OR) 1.4, 95% confidence interval
(CI) 1.0–2.0], in MOH-managed facilities than in
faith-based, private and other facilities (OR 1.2, 95%
CI 1.0–1.5), in central hospitals than in district
hospitals and health centres (OR 2.7, 95% CI 0.9–
7.9), and in larger facilities with EMRS than in smaller
facilities with paper-based records (OR 1.3, 95% CI
0.9–1.8).
Patient-level data
We analysed ART outcomes for 11 534 women who
started ART at the 19 large EMRS facilities since
September 2011 (see Table 1 for baseline characteristics).
Patients were followed for a total of 3501 person-years,
for a median [interquartile range (IQR)] duration of
3.3 (1.0–5.9) months. We compared across patient groups
the patients’ risk of not returning to the clinic after the
first visit or getting lost to follow-up thereafter. Com-
pared to patients who started ART for their own health,
Option Bþ patients who started ART while pregnant
were five times more likely to fail to return to the clinics
after the initial visit (adjusted OR 5.0, 95% CI 4.2–6.1)
and patients who started treatment while breastfeeding
were twice as likely to miss their first follow-up visit
(adjusted OR 2.2, 95% CI 1.8–2.8) (Table 2, Fig. 2). A
similar pattern was seen for LTF at the second visit,rized reproduction of this article is prohibited.
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Table 1. Baseline characteristics of all female patients aged 16–50 years starting antiretroviral therapy (ART) since 1 September 2011 in
19 facilities with electronic medical record systems.
Total
Non-pregnant
women starting
ART for their
own health
Pregnant women
starting ART
due to Option Bþ
Breastfeeding women
starting ART due
to Option Bþ
Number of patients 11534 6177 3320 2037
Median (IQR) age (years) 30.4 (25.9–35.8) 33.1 (28.3–38.8) 27.9 (23.8–31.7) 28.4 (24.6–32.5)
<30 (%) 5466 (47.4) 2058 (33.3) 2143 (64.6) 1265 (62.1)
30–39 (%) 4658 (40.4) 2835 (45.9) 1109 (33.4) 714 (35.1)
40 (%) 1410 (12.2) 1284 (20.8) 68 (2.1) 58 (2.9)
ART eligibility due to CD4þ cell count (%)
Eligible 2853 (24.7) 2731 (44.2) 39 (1.2) 10 (0.5)
Not eligible 117 (1.0) 50 (0.8) 112 (3.7) 28 (1.4)
Missinga 8564 (74.3) 3396 (55.0) 3169 (95.5) 1999 (98.1)
WHO clinical stage (%)
Stage 1 3072 (26.6) 2052 (33.2) 1020 (30.7) 0 (0.0)
Stage 2 494 (4.3) 434 (7.0) 60 (1.8) 0 (0.0)
Stage 3 3336 (28.9) 3239 (52.4) 97 (2.9) 0 (0.0)
Stage 4 465 (4.0) 452 (7.3) 13 (0.4) 0 (0.0)
Missing 4167 (36.1) 0 (0.0) 2130 (64.2) 2037 (100.0)
ART eligible due to CD4þ 350/ml or WHO stage 3/4 (%)
Eligible 6370 (55.2) 6142 (99.4) 218 (6.6) 10 (0.5)
Not eligible or missing 5164 (44.8) 35 (0.6) 3102 (93.4) 2027 (99.5)
HIV testing date missing (%) 1355 (11.8) 827 (13.4) 288 (8.7) 240 (11.8)
Year of ART start (%)
2011 5735 (49.7) 2901 (47.0) 1590 (47.9) 1244 (61.1)
2012 5799 (50.3) 3276 (53.0) 1730 (52.1) 793 (38.9)
Number (%) pregnant 3320 (28.8) 0 (0.0) 3320 (100.0) 0 (0.0)
Most frequent ART regimen (%)
d4T 3TC NVP 5819 (50.5) 5479 (88.7) 179 (5.4) 161 (7.9)
TDF 3TC EFV 5420 (47.0) 488 (7.9) 3090 (93.1) 1842 (90.4)
3TC, lamivudine; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; TDF, tenofovir.
aART eligibility assessment due to CD4þ cell count was missing if no CD4þ cell count was measured between 3 months before and 1 month after start of ART.although the level was much lower. Between months 3
and 6, LTF was low and similar across groups (Table 2).
Six months after ART initiation, the proportion of
women who had no follow-up visit after ART initia-
tion or were lost to follow-up reached 23.9% (95% CI
22.6–25.3%) in all Option Bþ patients, 29.4% (95%
CI 27.6–31.3%) in Bþ pregnant women, 16.1% (95% CI
14.3–18.0) in Bþ breastfeeding women and 9.6% (95%
CI 8.7–10.6%) in women with a low CD4þ cell count or
advanced clinical stage.
The proportion of women known to have died or
transferred to other clinics at 6 months after ART
initiation was higher among women who started ART for
their own health (Fig. 2) than among those who started
under Option Bþ. Documented mortality among
Option Bþ patients was low. Mortality over a period
of 6 months was 0.4% (95% CI 0.2–0. 7%) for Bþ
pregnant women, 0.5% (95% CI 0.2–0.9%) for Bþ
breastfeeding women and 3.0% (95% CI 2.6–3.6%) for
women who started ART for their own health. After
controlling for age and facility type, Option Bþ patients
who started ARTon the day of HIV testing were almost
twice as likely never to return to the clinic (adjusted OR
1.9, 95% CI 1.5–2.4) than were Option Bþ patients who
started ART later (P< 0.001).Copyright © Lippincott Williams & Wilkins. UnautAmong pregnant Option Bþ patients (the group with the
highest risk of no follow-up after ART initiation) the
proportion of women who had no follow-up visit after
ART initiation varied from 1.2 to 42.5% between
facilities. Much of this variation could be explained by
facility-level factors: facilities with the largest proportions
of Bþ pregnant women had the largest proportion of
these women with no follow-up visits (Figure S1, http://
links.lww.com/QAD/A452). Facilities that offered
additional adherence counselling to that required by
national guidelines (e.g. peer counselling by mother
mentors) had lower rates of early LTF (Table S1, http://
links.lww.com/QAD/A452).
An analysis of time from HIV diagnosis to ART initiation
included a total of 10 179 patients. Over a third (35%) of
all pregnant Option Bþ patients with a known HIV
testing date began ART on the day they were diagnosed
(n¼ 1072/3032; n¼ 288 missing HIV testing date). The
median (IQR) time from HIV diagnosis to ART
initiation was 9 (0–64) days for pregnant Option Bþ
patients, 141 (16–351) days for breastfeeding Option Bþ
patients and 76 (15–480) days for patients who started for
their own health (Fig. 3). Results were similar when we
restricted the analysis to facilities with less than 5%
missing values in HIV testing date (data not shown).horized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Fig. 2. Cumulative incidence of outcomes on antiretroviral
therapy (ART) since the introduction of Option BR. The
panels show the cumulative incidence of treatment outcomes
over time from the start of ART in months. Treatment out-
comes are compared across three groups based on patients’
indication for ART: Option Bþ indication and ART start
during pregnancy (a), Option Bþ indication and ART start
after delivery while breastfeeding (b) and WHO stage 3 or 4
and/or CD4þ 350/ml or less (c). Estimates are derived from
competing risk regression.
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Fig. 3. Time from HIV testing to initiation of antiretroviral
therapy (ART). Kaplan–Meier functions for the time from
HIV testing to initiation of ART among patients who started
ART. Separate functions are shown for patient who started
ART with Option Bþ indication during pregnancy (’Option
Bþ pregnant’), with Option Bþ indication after delivery while
breastfeeding (’Option Bþ breastfeeding’) and in WHO
clinical stage 3 or 4 and/or CD4þ 350/ml or less (‘ART for
own health’).Discussion
Under Option Bþ, on average, 17% of all women were
lost to follow-up 6 months after ART initiation. In the
19 large facilities with EMRS and available patient-levelCopyright © Lippincott Williams & Wilkins. Unautdata, we found higher LTF (24%). Compared to women
who initiated ART for their own health, women who
started ART to prevent MTCT during pregnancy were
five times more likely never to return to the clinic after
they initiated ART. Women who began ART while
breastfeeding were twice as likely to not return compared
to those who started for their own health. More than one-
third of all pregnant Option Bþ patients initiated ARTon
the day of diagnosis, and members of this group were
almost twice as likely never to return to the facilities after
the initial visit as pregnant Option Bþ patients who
started later. There was extensive variation in the level of
LTF between clinics, ranging from 0 to 58% at 6 months
after ART initiation. Notably, the risk of LTF was highest
in facilities where the patient cohort contained a large
proportion of Option Bþ patients.
Our results confirm and extend previous studies on
retention in care under Option Bþ in Malawi. In these
studies, 17 and 22% of all women who started ARTwith
an Option Bþ indication were lost to follow-up 6 and
12 months after ART initiation [6,16]. The 7% point
higher rate of LTF that we found in larger facilities with
available patient-level data may be caused by health-
system factors affecting retention (e.g. overburdened staff,
ability to capture and report data), which may be less
favourable in larger ART programmes [22]. A recent
study conducted at a large urban maternity unit in Malawi
also reported high initial LTF and a retention rate below
the national average [23]. But it is also possible thathorized reproduction of this article is prohibited.
Co
596 AIDS 2014, Vol 28 No 4misclassification of patients (e.g. unaccounted transfers) as
lost to follow-up is more common in larger facilities:
these facilities are located in more urban regions with a
mobile population.
There are several possible reasons Option Bþ patients are
more likely to be lost to follow-up than those who start
ART for their own health. Some women may find
PMTCT intervention coercive [24]. High dropout rates
could reflect women’s resistance to starting ART. Some
early dropouts may never have started ART, or have
stopped after the first dose in the health facility. It is also
possible that Option Bþ women may have been less well
prepared for ART, and thus less likely to adhere to
treatment and to attend follow-up visits [25,26]. Our
findings of better retention in care in patients who did not
start ART on the day of diagnosis, and in those who
received additional counselling may support this idea.
However, the reasons and consequences for differences in
the timing of ART initiation require further investi-
gation. More time to prepare for ART initiation may also
be the reason why patients who started ART while
breastfeeding may have had more time to prepare for
ART than those who initiated ART before delivery. This
may have lowered the former’s risk of LTF. Women who
start ART immediately do not have the chance to disclose
their HIV status to spouses or relatives, and prior
disclosure may improve ART adherence [25]. On the
contrary, non-disclosure was frequent among pregnant
women who feared stigmatization, divorce and physical
violence even before Option Bþ was implemented
[27,28]; and there is limited empirical evidence to
document the advantages of systematically delayed ART
[29]. Finally, patients who are lost to follow-up may have
died or transferred to another facility without EMRS
documentation and thus have been misclassified as lost to
follow-up [30]. Unaccounted transfers are a common
problem in Malawi [31], but under-recording of death is
unlikely to be common in Bþ pregnant women, given
the relative good health of HIV-infected pregnant
women. High LTF and poor PMTCT coverage have
been described under Option A and B [5]; many of the
factors causing poor retention may therefore not be
specific to Option Bþ, but a general problem of PMTCT.
The strength of this analysis is that it combines insights
from a large longitudinal patient-level dataset with those
from facility-level data with national coverage. We were
able to evaluate differences in LTF across specific
categories of women, including Option Bþ women
who started ART before and after delivery. We analysed
patient-level data and described predictors of LTF during
different points after ART initiation. Precise HIV testing
date allowed us to describe time elapsed between HIV
testing, ART initiation and clinical outcomes.
The study has also several limitations. We lacked
information on date of delivery, parity, gestational agepyright © Lippincott Williams & Wilkins. Unauthoat ART initiation, duration of breastfeeding and relevant
health-system indicators. Although we evaluated associ-
ations between some facility and patient-level character-
istics and patient outcomes, we could not rely on
information about psychosocial and structural determi-
nants of retention in care (e.g. coercion and resistance to
starting ART). The short length of follow-up duration
and the fact that our data were confined to adult patients
on ART prevented us from assessing potential long-term
benefits of Option Bþ like decreased child morbidity and
mortality. In Malawi, electronic data entry and monitor-
ing does not start when positive HIVþ status is
determined and women become eligible for ART.
Instead, data collection begins at time of ART initiation,
a condition that limited our ability to assess PMTCT
coverage under Option Bþ. Finally, patients who
transferred to another facility had to be excluded from
facility-level data to avoid double counting. The analysis
of facility-level predictors of LTF may have been biased by
the exclusion of these patients because the proportion of
transfers varied greatly between facilities.
In summary, in the first months after Option Bþ was
implemented in Malawi, the number of pregnant and
breastfeeding women who started lifelong ART sub-
stantially increased, and the time between the first positive
HIV test and treatment start decreased. Almost a third of
the facilities in Malawi have an excellent retention level.
However, high early LTF found in many other facilities is
of concern and underlines the pressing need to under-
stand the barriers to retention in care for women who
start ART under Option Bþ. Our findings support the
need for innovative service delivery models like
community or family-based approaches and interventions
to promote retention such as motivating text messages
[32], systematic defaulter tracing or improving con-
fidentiality in PMTCT. LTF was particularly high in
facilities with a high patient volume and in patients
who start ART during pregnancy on the day of HIV
diagnosis – when policy makers plan improvements to
Option Bþ, they should therefore pay particular attention
to these patients.Acknowledgements
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